Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Keertik Fulzele"'
Autor:
Noopur Raje, Chukwuamaka Onyewadume, Cristina Panaroni, Ka Tat Siu, Keertik Fulzele, Tomoaki Mori, Allison Maebius
Publikováno v:
Blood
Adipocytes occupy 70% of the cellular volume within the bone marrow (BM) wherein multiple myeloma (MM) originates and resides. However, the nature of the interaction between MM cells and adipocytes remains unclear. Cancer-associated adipocytes suppor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0a6d146a64ec44a9f9f85b66a9b719d
https://doi.org/10.1182/blood.2021013832
https://doi.org/10.1182/blood.2021013832
Autor:
Keertik Fulzele, Kimberly Wagner, Astha Malik, Sylvie Guichard, Jennifer Korpik, Adam Drake, Mengna Chi, Punam Malik, Archana Shrestha
Publikováno v:
Blood Adv
Sickle cell anemia (SCA) results from an abnormal sickle hemoglobin (HbS). HbS polymerizes upon deoxygenation, resulting in red blood cell (RBC) sickling and membrane damage that cause vaso-occlusions and hemolysis. Sickle RBCs contain less adenosine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9af289404a49ceda89f3e83f1c6d75b
https://doi.org/10.1182/bloodadvances.2020003604
https://doi.org/10.1182/bloodadvances.2020003604
Autor:
Franziska Kuhlee, Karl Hackmann, Keertik Fulzele, Rahul Kumar, Valentina R. Minciacchi, Costanza Zanetti, Soraya Hoelper, Christina Karantanou, Paola Divieti Pajevic, Sara Zia-Chahabi, Stefan Müller, Joseph Emmerich, Rosemary Dray-Spira, Marie Joelle Jabagi, Michaela Fontenay, Divij Verma, Daniela S. Krause, Raquel S. Pereira, Philip Wenzel, Kathrin Kunz, Evelin Schroeck, Natalie Filmann
Publikováno v:
Blood. 134:227-238
Vitamin K antagonists (VKAs) have been used in 1% of the world’s population for prophylaxis or treatment of thromboembolic events for 64 years. Impairment of osteoblast function and osteoporosis has been described in patients receiving VKAs. Given
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88bb1617de53a4f90e4339bca3951239
https://doi.org/10.1182/blood.2018874214
https://doi.org/10.1182/blood.2018874214
Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease
Autor:
Patricia Schroeder, Keertik Fulzele, Sanjeev Forsyth, Maria D. Ribadeneira, Sylvie Guichard, Erik Wilker, C. Gary Marshall, Adam Drake, Rose Fessler, Diamantis G. Konstantinidis, Katie G. Seu, Theodosia A. Kalfa
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 380(3)
Etavopivat is an investigational, oral, small molecule activator of erythrocyte pyruvate kinase (PKR) in development for the treatment of sickle cell disease (SCD) and other hemoglobinopathies. PKR activation is proposed to ameliorate the sickling of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4cbce16bbd434376b51615d214eb089
https://pubmed.ncbi.nlm.nih.gov/35031585
https://pubmed.ncbi.nlm.nih.gov/35031585
Autor:
Margaret Eberle, Yuhei Uda, Chris Adamson, Forest Lai, Joseph H Garcia, Louis C. Gerstenfeld, Paola Divieti Pajevic, Sean Dougherty, Keertik Fulzele, Amira I. Hussein, Lowell Misener, Jordan M Spatz, Chris Dedic
Publikováno v:
The FASEB Journal. 35
Bone loss is a major health concern for astronauts during long-term spaceflight and for patients during prolonged bed rest or paralysis. Growing evidence suggests that osteocytes, the most abundant cells in the mineralized bone matrix, play a key rol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3af64b64da768a9cbc12d39c7950f5fa
https://doi.org/10.1096/fj.202100059r
https://doi.org/10.1096/fj.202100059r
Autor:
Valentina Nardi, Rakesh Verma, Keertik Fulzele, Elizabeth O'Donnell, Tomoaki Mori, Rie Nakamoto-Matsubara, Cristina Panaroni, Andrew R. Branagan, Andrew Yee, Noopur Raje
Publikováno v:
Blood. 138:398-398
The treatment of multiple myeloma (MM) continues to evolve with new drugs, resulting in dramatically improved outcomes. Despite these advances, MM remains an incurable disease, with Extraosseous/Extramedullary disease (EMD) playing a major role in th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bd99725fd618efe15720b4620a1cba18
https://doi.org/10.1182/blood-2021-152784
https://doi.org/10.1182/blood-2021-152784
Autor:
Cristina Panaroni, Keertik Fulzele, Tomoaki Mori, Rie Nakamoto-Matsubara, Allison Maebius, Noopur S. Raje
Publikováno v:
Blood. 138:1614-1614
Obesity-induced increases in bone marrow adipocyte (BMAd) numbers and volume are associated with an increased risk of multiple myeloma (MM). We analyzed gene expression from previously published public datasets and found that 11 out of 47 genes assoc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6f94b16e0729ed29f335121be5e4b80
https://doi.org/10.1182/blood-2021-154110
https://doi.org/10.1182/blood-2021-154110
Autor:
Keertik Fulzele, Cristina Panaroni, Chukwuamaka Onyewadume, Tomoaki Mori, Noopur Raje, Allison Maebius
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S19
Background Obesity-induced increases in bone marrow adipocyte (BMAd) numbers and volume are associated with an increased risk of MM. However, the associated molecular mechanisms have remained largely unknown. We hypothesize that BMAd support MM cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cc3262f0f84cf192623d225f7824d540
https://doi.org/10.1016/s2152-2650(21)02103-0
https://doi.org/10.1016/s2152-2650(21)02103-0
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S97
Background MYC upregulation is associated with multidrug refractory patients in multiple myeloma (MM). We isolated patient derived MM cells with high MYC expression and discovered that NCOR2 was down-regulated in these cells. NCOR2 is a transcription
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d1333b9e5e8684c2d2b8e42df8ed51be
https://doi.org/10.1016/s2152-2650(21)02241-2
https://doi.org/10.1016/s2152-2650(21)02241-2
Autor:
Paola Divieti Pajevic, Keertik Fulzele
Publikováno v:
Current Molecular Biology Reports. 3:71-78
Since its discovery 15 years ago, inhibition of sclerostin has come to be identified as a potent anabolic agent. The sclerostin neutralizing antibody, romosozumab, is a promising treatment for postmenopausal osteoporosis. Animal studies also show a r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d0604af21a7fdad0fbe4af385b8cfc2a
https://doi.org/10.1007/s40610-017-0061-y
https://doi.org/10.1007/s40610-017-0061-y